Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan to Swiftly Consider Safety Measures over Tavneos: Minister
Japanese Health Minister Kenichiro Ueno said on May 18 that the government will “swiftly consider” the necessary safety measures for Kissei Pharmaceutical’s vasculitis treatment Tavneos (avacopan) after the company disclosed fatal liver injury cases in Japan. “We are also scrutinizing…
To read the full story
Related Article
- Tavneos Data Integrity Issue Could Spill Over to Japan, Investigator Warns
June 2, 2026
- Kissei Drops Call to Halt New Tavneos Use after Blue Letter Action
May 22, 2026
- Update: Tavneos Slapped with Blue Letter Action in Japan over Liver Injury Risk
May 22, 2026
- MHLW Orders Detailed Report on Tavneos Efficacy Concerns
May 20, 2026
- Kissei Urges Halt to New Tavneos Use after Fatal Liver Injury Reports
May 18, 2026
REGULATORY
- Japan Govt Likely to Slim Down Honebuto, but Details Remain Elusive
June 8, 2026
- Leqembi, Kisunla Labels Revised to Strengthen ARIA Monitoring
June 8, 2026
- Japan Tightens Oversight of Mounjaro Resales: Health Minister
June 8, 2026
- LDP Panel Finalizes Honebuto Proposal on Preventive Care, Adds Obesity Focus
June 5, 2026
- Ex-GSK Japan Head Calls for End to "Obsolete" 14-Day Prescription Limit
June 5, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…